Titlebook: Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract; From Surgery to Targ Eric Raymond,Sandrine Faivre,Philippe Rusznie

召集會(huì)議

書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract影響因子(影響力)




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract影響因子(影響力)學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract網(wǎng)絡(luò)公開度




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract被引頻次




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract被引頻次學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract年度引用




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract年度引用學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract讀者反饋




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract讀者反饋學(xué)科排名

草本植物

NEX

Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroend dual-targeting chimeric molecules. Conjugation of SST analogs with radionuclides has also been used for peptide-receptor-targeted radiotherapy (PRRT) in advanced NETs, with promising results. This chapter summarizes key preclinical and clinical data on the antisecretory and antitumor effects of S

ALE

Streptozocin-Based Chemotherapy: Still a Standard of Care for Neuroendocrine Tumours?, therapies and this may be important in those who are symptomatic from tumour burden and those with locally advanced disease who may be down-staged for resection. The role of Ki67 and other predictive markers requires further assessment in prospective studies as does the relative efficacy of alterna

試驗(yàn)

GUISE

Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors, trial. In this later study, sunitinib demonstrated significant benefits in terms of progression-free survival and response rate in patients with advanced well-differentiated pancreatic neuroendocrine tumors. The safety profile in this patient population was consistent with previously reported data

auxiliary

Clinical Management of Targeted Therapies in Neuroendocrine Tumours,ons, and providing strategies to overcome them is a further important component of patient care. At the core of clinical management is effective communication between patients and physicians, which ensures patients are fully involved in decisions concerning their care, and will allow advances in the

擁護(hù)者

Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies,ving targeted agents. In this chapter, we aimed to review the various imaging techniques used to characterize neuroendocrine tumors in routine clinic and clinical trials. We also challenge the potential advantages of those imaging techniques for the evaluation of response in patients with neuroendoc

中世紀(jì)

Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumorsesponse) resistance to antiangiogenic agents and mTOR inhibitors, using data available from preclinical and clinical studies in various malignancies. Herein, we also describe how these general mechanisms of resistance may emerge in patients with PNET treated with sunitinib and everolimus. Overcoming

ECG769